Compare ADMA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADMA | GHRS |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | 73 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2012 | 2021 |
| Metric | ADMA | GHRS |
|---|---|---|
| Price | $9.15 | $26.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $25.67 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 3.6M | 242.2K |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $42,219,783.00 | N/A |
| Revenue This Year | $27.46 | N/A |
| Revenue Next Year | $22.11 | N/A |
| P/E Ratio | $48.79 | ★ N/A |
| Revenue Growth | ★ 43.85 | N/A |
| 52 Week Low | $7.21 | $11.32 |
| 52 Week High | $20.46 | $28.96 |
| Indicator | ADMA | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 61.07 |
| Support Level | $7.38 | $12.88 |
| Resistance Level | $11.42 | $28.96 |
| Average True Range (ATR) | 0.32 | 1.69 |
| MACD | 0.10 | 0.09 |
| Stochastic Oscillator | 84.09 | 71.44 |
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.